David Glenn
Known title: Executive Vice PresidentCIK: 0001606256
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Goldman Sachs initiates Zoetis coverage with Neutral rating. Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.
Transaction History
| PAHC | ▲ Buy | Grant | 3,334 | $0 | 8/6/2026 | View on chart |
| PAHC | ▼ Sell | Other | 840 | $31K | 8/4/2026 | View on chart |
| PAHC | ▼ Sell | Other | 12,528 | $647K | 2/11/2026 | View on chart |
| PAHC | ▲ Buy | Option Exercise | 30,000 | — | 2/9/2026 | View on chart |
| PAHC | ▲ Buy | Grant | 4,845 | $0 | 8/15/2025 | View on chart |
| PAHC | ▲ Buy | Option Exercise | 30,000 | — | 2/9/2025 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 7,712 | $355K | 2/23/2022 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 24,678 | $2.2M | 2/23/2022 | View on chart |
| ZTS | ▼ Sell | Open Market | 7,046 | $1.3M | 2/23/2022 | View on chart |
| ZTS | ▼ Sell | Open Market | 19,415 | $3.7M | 2/23/2022 | View on chart |
| ZTS | ▼ Sell | Open Market | 5,929 | $1.1M | 2/23/2022 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 6,247 | — | 2/12/2022 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 2,336 | $465K | 2/12/2022 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 21,543 | — | 2/12/2022 | View on chart |
| ZTS | ▼ Sell | Tax Withholding | 9,869 | $2.0M | 2/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Phibro Animal Health (PAHC) Draws Attention Amid Small-Cap Review
Phibro Animal Health (PAHC) is currently the focus of market attention, with recent articles discussing whether it is the right time to hold the stock. The company is also highlighted in a list of small-cap stocks showing warning signs. This news provides context for the stock's current position within its 52-week range, which spans from $28.25 to $60.08.
Phibro Animal Health (PAHC) Draws Attention Amid Small-Cap Review. Phibro Animal Health (PAHC) is currently the focus of market attention, with recent articles discussing whether it is the right time to hold the stock. The company is also highlighted in a list of small-cap stocks showing warning signs. This news provides context for the stock's current position within its 52-week range, which spans from $28.25 to $60.08.